Mesoblast Limited (NASDAQ:MESO) Position Increased by Fi3 FINANCIAL ADVISORS LLC

Fi3 FINANCIAL ADVISORS LLC raised its position in shares of Mesoblast Limited (NASDAQ:MESO) by 75.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,625 shares of the company’s stock after buying an additional 15,725 shares during the quarter. Fi3 FINANCIAL ADVISORS LLC’s holdings in Mesoblast were worth $725,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Strategic Financial Concepts LLC acquired a new position in shares of Mesoblast in the 4th quarter valued at about $2,744,000. Jane Street Group LLC increased its holdings in shares of Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares during the period. Clayton Financial Group LLC acquired a new position in shares of Mesoblast in the 4th quarter valued at about $275,000. Ballentine Partners LLC acquired a new position in shares of Mesoblast in the 4th quarter valued at about $222,000. Finally, Lindbrook Capital LLC increased its holdings in shares of Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after purchasing an additional 901 shares during the period. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Stock Performance

Shares of Mesoblast stock opened at $13.94 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The stock has a 50 day moving average price of $16.66 and a two-hundred day moving average price of $12.86. Mesoblast Limited has a 12-month low of $2.05 and a 12-month high of $22.00.

Wall Street Analyst Weigh In

MESO has been the topic of a number of research reports. Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a report on Tuesday, March 4th. Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $24.00 target price (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Mesoblast presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.